> BPC-157 tendon research: what the rodent studies examined

BPC-157 tendon research: what the rodent studies examined

October 22, 2026

Prepared by: Research Desk

Prepared by: Research Desk. Sources are linked for verification.

Status: Not approved. BPC-157 is not FDA-approved for any use and is prohibited at all times under the WADA anti-doping code. See our legal status file.

Search for "BPC-157 tendon" and confident claims appear quickly. The research behind those claims is narrower than the marketing implies. Almost all published tendon work on BPC-157 comes from experiments in rats. This explainer covers what those experiments examined and what kind of evidence they are. It also explains why the step from a rat tendon to a human tendon has not been taken in a controlled trial.

For the full picture across all tissues and the reported side effects, see our evidence guide. This page stays on tendons and the muscle-tendon junction.

Why tendons became a focus

BPC-157 is a synthetic 15-amino-acid peptide described as derived from a protein in human gastric juice. Its early research focused on the stomach and gut. Over time, the same research group began publishing on other tissues, including skin, muscle and tendon. A 2021 review by that group, Seiwerth and colleagues, places tendon work within a wider programme of wound-healing experiments across many tissue types [1]. Read it as a summary written by the researchers who ran most of the original studies. It is not an independent appraisal.

Sports medicine has picked up the topic. A 2025 systematic review in orthopaedic sports medicine reports that BPC-157 is increasingly used in sports-medicine settings and by athletes. The same review notes that it lacks FDA approval and is banned in professional sport [2]. Interest has grown faster than the human evidence.

What the rodent tendon studies examined

The models

Rodent soft-tissue research of this kind generally follows a common design. Researchers create a tendon or muscle-tendon injury on purpose, under controlled laboratory conditions. They compare animals given BPC-157 with control animals, then assess outcomes at set time points. Outcome types commonly seen in animal musculoskeletal research include:

Functional measures: how the animal walks and uses the limb.
Biomechanical measures: how much load the repaired tissue tolerates before failure.
Macroscopic appearance: what the injury site looks like when examined.
Histology: tissue structure under the microscope, such as fibre organisation and cell types.

The Vasireddi systematic review draws on this preclinical literature and sets it beside the much smaller human record [2]. Whatever direction the animal results point, they remain statements about what rat experiments reported. They are not a demonstration of any effect in people.

The myotendinous junction study

One frequently cited paper targets the point where muscle meets tendon. Japjec and colleagues (2021, Biomedicines) studied experimentally disabled myotendinous junctions in rats [3]. The title presents BPC-157 as a "therapy" for those junctions. That word reflects the authors' framing of an animal experiment. It does not describe human use. The study is a rat surgical model, and like most work in this area it comes from the same Croatian research network.

Muscle as neighbouring tissue

A tendon cannot be fully separated from the muscle it anchors. Staresinic and colleagues (2022) reviewed BPC-157 research on striated, smooth and heart muscle [4]. This is a review of mostly animal work by the same group. It offers context on how they model muscle injuries, but it is not tendon-specific evidence.

How to read these findings

The rodent tendon literature is often described online as "consistently positive". That description can be accurate and still say little about people. Several features shape what the results can and cannot support.

Species gap. Rat tendons are small laboratory tissue, typically in young, genetically similar animals. Human tendon problems often involve years of loading, age-related change and other conditions. A rat result is a starting hypothesis, not a forecast.

Single-group concentration. Most of the tendon studies come from one research network [1][3][4]. Independent replication by unrelated laboratories is the usual test of whether a finding holds. For BPC-157 tendon work, that replication remains limited.

Acute injury models. Many experiments use a fresh, surgically created injury. Long-standing tendon pain in people is a different situation. A model built on acute injury cannot settle questions about chronic conditions.

Outcome selection. Rodent studies often report several outcomes at several time points. Without preregistration, readers cannot always tell which outcomes were planned in advance.

Reviews by the original authors. Narrative reviews written by the originating group [1][4] summarise their own work. Systematic reviews by outside authors [2] carry more weight on how strong the evidence is overall. Even those can only grade what has been published.

The human evidence on tendons

No randomized controlled trial of BPC-157 for any tendon condition appears in the sources we track. The human literature on BPC-157 overall consists of a few small reports.

Knee pain report (2021). Lee and Padgett described intra-articular injection of BPC-157 in people with various types of knee pain [5]. It is a small, uncontrolled report on knee pain in general, not a tendon trial. Without a control group, it cannot separate any effect of the peptide from natural recovery, expectation or other care.
Intravenous safety pilot (2025). Lee and Burgess published a small pilot study on the safety of intravenous infusion in humans [6]. It was designed around safety and tolerability, not tendon outcomes.
Human-evidence systematic review (2026). Poolton and colleagues systematically reviewed human evidence for BPC-157 in orthopaedic and regenerative medicine, covering both efficacy and safety [7]. A review of this kind can only be as strong as the human studies it finds, and controlled tendon studies are not among the reports listed above.

Sports-medicine journals have also published broader reviews. DeFoor and colleagues' 2025 Arthroscopy review is titled as a question: whether injectable peptides are an adjunct to regenerative medicine and sports performance [8]. Tewari and colleagues reviewed peptide supplements in sports medicine in 2026 [9]. Neither substitutes for a controlled human tendon trial.

Safety and status context

The lack of human tendon trials also means there is no controlled human safety data specific to tendon use. FDA's page of bulk substances for compounding that may present significant safety risks includes an entry for BPC-157. On the version reviewed for our legal status file, it sits among substances whose nominations were withdrawn by the nominators, and the entry still records concerns including possible immunogenicity for certain routes of administration [10]. FDA's Pharmacy Compounding Advisory Committee met on 23–24 July 2026 [13]. FDA's MedWatch programme is the official channel for reporting adverse events linked to products [11]. WADA publishes its Prohibited List, which governs athletes in tested sport [12]. Our legal status file has the dated detail.

Comparing training-load wearables on neutral criteria

Sport-science research on tendons often tracks training load, meaning how much running, jumping or lifting an athlete does over time. Some readers who follow this research use consumer wearables to log their own activity data. A well-chosen device produces records that can be exported, compared and checked. When comparing devices, these neutral criteria are a practical place to begin:

Validation: whether independent studies have compared the device's heart-rate, distance or step data against laboratory reference equipment, and whether that testing covered high-intensity efforts as well as steady activity.
What is measured: optical wrist heart rate, chest-strap electrical heart rate, GPS distance or accelerometry. Each sensor type has different strengths, so match the sensor to the activity being logged.
Data export: whether raw data can be exported in standard file formats for independent analysis, or only viewed inside an app.
Price transparency: the total cost over time, including any subscription needed to unlock training-load metrics.
Data privacy: where data are stored, whether they are shared with third parties, and whether they can be fully deleted.
Format and battery: watch, strap or clip-on form, and whether battery life covers long sessions without gaps in the record.

A tracker records activity. It does not diagnose injuries, and its "readiness" or "strain" scores are proprietary estimates rather than validated medical measures. Those scores are best read as descriptive data, not as verdicts.

How this site handles affiliate links, and what it will never link to, is set out on our About page.

Frequently asked questions

Has BPC-157 been tested on human tendons?

Not in a controlled trial, according to the sources we track. The human literature consists of a few small reports, such as a knee pain series and an intravenous safety pilot, and neither is a tendon trial [5][6]. A 2026 systematic review gathered the human evidence in orthopaedic and regenerative medicine, and it can only be as strong as those few studies [7].

What did the rat tendon studies examine?

They used deliberately created injuries in laboratory rats and compared animals given BPC-157 with controls. One study examined experimentally disabled myotendinous junctions in rats [3]. These are laboratory outcomes in animals, not results in people.

Why are rodent results not enough?

Rat tendons, acute surgical injuries and young laboratory animals differ substantially from human tendon conditions. Most of the studies also come from one research network, and independent replication is limited [1][3][4]. Animal findings generate hypotheses that only controlled human trials can test.

Last updated: 19 October 2026.

Related on this site

Not medical advice. This page reports published research and regulatory records for information only.

Research-only notice: Content on this site is provided for research and educational purposes only and is not intended for human use. It is not medical advice.

Translation notice: Some content on this site may have been machine-translated using Google Translate and may contain errors.